Immunic advances Phase 3 MS program, eyes topline data by year-end

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Wednesday it remains on track to deliver top-line phase 3 data for its lead multiple sclerosis drug candidate,...